Pedro Correa de Sampaio

Pedro Correa de Sampaio has a long and varied work experience. In 2021, they became Co-founder and CEO of Neobe Therapeutics. In 2020, they were a Project Consultant for Triumvira Immunologics, Inc. and a Founding Analyst for Deep Science Ventures, exploring venture opportunities in the solid tumor microenvironment field. From 2012-2020, they were a Post-doctoral fellow at MD Anderson Cancer Center, where they developed a new multiplex staining technology and collaborated with bioinformatics teams to create new algorithms. From 2008-2012, they were a Scientific Officer at the University of Cambridge, where they applied a 3D in vitro co-culture model of tumor angiogenesis to identify new inter-cellular mediators of this process. From 2006-2008, they were a MSc Student at the Faculdade de Ciências da Universidade de Lisboa.

Pedro Correa de Sampaio obtained a Doctor of Philosophy - PhD in Oncology and Cancer Biology from the University of Cambridge between 2008 and 2012. Prior to that, they obtained a Licenciatura in Biology from the Faculdade de Ciências da Universidade de Lisboa between 2002 and 2006.